--- canonical_url: https://www.stockexpertai.com/earnings/wst last_updated: 2026-05-09T17:12:32.576Z --- # West Pharmaceutical Services, Inc. (WST) Q4 FY2026 Earnings Preview > This content was automatically generated with FMP live data + Q1 FY2026 earnings call transcript. Generated: 2026-05-09T17:12:32.139Z. Educational tool, not investment advice. --- ## Quick Summary | Field | Value | Source | |---|---|---| | Price | $325.92 (▲ 1.21%) | fmp:quote | | Market Cap | $23.0B | fmp:profile | | 52w range | $202.79 – $328.44 | fmp:quote | | Earnings | Thu 23 Jul | fmp:earnings-history | | EPS estimate | $2.06 (+12% YoY) | fmp:earnings-estimate | | Revenue estimate | $839.2M | fmp:earnings-estimate | | Beat streak | 7/4 | fmp:earnings-history | | Rating | B+ (overall 3/5) | fmp:ratings | | Analyst median target | $315 (-3.4% upside) | fmp:price-target-consensus | | MoonshotScore | 49/100 | derived | | Council | 2/6 bullish | derived | | Munger verdict | Overvalued | derived | ## West Pharmaceutical Services, Inc. — Q4 FY2026 Expectations Q4 consensus: revenue $839.2M^{[FMP est]}, EPS $2.06^{[FMP est]}. 7 consecutive quarters of beat^{[FMP earnings]}. ## Quick Take **Score:** B+ · **Stance:** SELL · **Council:** 2/6 · **Moonshot:** 49 = MoonshotScore 49^{[9-pillar formula]} + Council 2/6^{[6-lens rule]}. Form 4: 0 transactions^{[FMP Form 4]}. ## Watchlist (6 metrics) ### 1. Capex Efficiency West continues to drive a focus on increased capital spending efficiency and remains on track with expectations of $250 million to $275 million for the year, even as it increases its revenue guidance. > "Capital expenditures were $43 million, down from $71 million in the prior year as we continue to drive a focus on increased capital spending efficiency. And we remain on track with our expectations of $250 million to $275 million for the year, even as we increase our revenue guidance, which I'll talk about shortly." > — Robert McMahon, CFO, Risk Indicator · Q1 FY2026 ### 2. Organic Revenue Growth Guidance West has increased its full year 2026 organic revenue growth expectation to 7% to 9%, up from its previous guide of 5% to 7%. > "We now anticipate full year organic revenue growth back to our long-term construct of 7% to 9%, up from our previous guide of 5% to 7%, and adjusted EPS increased to the range of $8.40 to $8.75." > — Eric Green, CEO, Expectation / Guide · Q1 FY2026 ### 3. Hvp Components Growth HVP components represents 48% of the company's total net sales and continues to be the key growth driver for West, growing 23% on an organic basis in the first quarter. > "Starting with HVP components in our proprietary Products segment, which represents 48% of our company's total net sales and continues to be the key growth driver for West. HVP components grew 23% on an organic basis in the first quarter." > — Eric Green, CEO, Investor Focus · Q1 FY2026 ### 4. Fy26 Revenue Guidance Increase West is increasing its revenue and adjusted EPS guidance for full year 2026 due to strong first quarter performance and the expected ongoing momentum in its business. > "As announced in the press release today, due to our strong first quarter performance and the expected ongoing momentum in our business, we are increasing our revenue and adjusted EPS guidance for full year 2026." > — Eric Green, CEO, Expectation / Guide · Q1 FY2026 ### 5. Glp 1 Revenue Contribution HVP components GLP-1 revenues grew significantly and contributed 10% of total company sales consistent with the previous quarter. > "HVP components GLP-1 revenues grew significantly and contributed 10% of total company sales consistent with the previous quarter." > — Eric Green, CEO, Investor Focus · Q1 FY2026 ### 6. Biologics Growth This business continues to be a strong growth driver for our HVP components business and delivered 26% organic growth. > "This business continues to be a strong growth driver for our HVP components business and delivered 26% organic growth." > — Eric Green, CEO, Investor Focus · Q1 FY2026 ## MoonshotScore Pillars | Pillar | Score | Level | Evidence | |---|---|---|---| | Revenue Growth | 5.0 | medium | Q1 vs Q2: healthy growth (+10.3%) | | Gross Margin | 4.0 | medium | Q1: average margin (35.1%) | | Operating Leverage | 2.0 | weak | op margin healthy (21.0%) | | Cash Runway | 8.0 | strong | FCF strong ($0.0B FCF, covers CapEx) | | R&D Intensity | 3.0 | weak | low R&D investment (2.3%, weak innovation) | | Price Momentum | 4.0 | medium | RSI 77.7 overbought, 50d above | | News Sentiment | 8.0 | strong | strong buy consensus (80%) | **Formula:** sum(pillar.score) / (count * 10) * 100. Each pillar deterministic from FMP. Source maps in pillar.formula. ## Council (7-Lens) | Name | Stance | Context | |---|---|---| | Ray Dalio | neutral | macro · target upside -3.4% | | Ken Griffin | bull | flow · 50d MA above | | Jim Simons | bear | quant · RSI 78 | | Klarman | bear | value · target upside -3.4% | | Buffett | bull | quality · ROE score 5/5 | | Munger | bear | valuation · target upside -3.4% | **Formula:** Each lens uses deterministic rule on bundle data. Logged in member.contextTr. ## Munger Lens - **Verdict:** Overvalued - **Financial Health:** Moderate - **Margin of Safety:** Weak - **Interest Coverage:** Adequate - **ROIC vs WACC:** Healthy **Formula:** verdict=upside>25?Undervalued:>0?Fairly Valued:Overvalued. Each lens deterministic from FMP ratings + priceTarget. ## Technical Levels - **RSI(14):** 77.7 — overbought (RSI 77.7) — geri çekilme baskısı - **50d MA:** $265 — hisse %23.0 üstünde — kısa vadeli destek - **200d MA:** $262 — hisse %24.6 üstünde — uzun vadeli destek - **Volume (10d):** +7% ## Past Performance (4 Quarters) | Quarter | EPS Actual | EPS Estimate | Result | Reaction | |---|---|---|---|---| | Q2 FY25 | $1.84 | $1.51 | BEAT | -5.6% | | Q3 FY25 | $1.96 | $1.68 | BEAT | -3.2% | | Q4 FY25 | $2.04 | $1.83 | BEAT | +2.8% | | Q1 FY26 | $2.13 | $1.68 | +26.8% EPS | -1.1% | Q1 (April 23, 2026): EPS $2.13 vs $1.68 est^[FMP], +26.8% beat. D+1 movement: -1.1%^{[FMP D+1]}. Decline despite beat — market reacted to guidance, not numbers. ## 3 Scenarios ### Scenario A · Beat **Q4 EPS > $2.06 + CapEx discipline** Threshold: EPS > $2.06^{[FMP est]}. Target: Break above median target $315^{[FMP target]}; high target $340^[FMP] upper bound. ### Scenario B · In-Line **EPS ≈ $2.06 + CapEx < $42.7M** Threshold: EPS ≈ $2.06^{[FMP est]}, Q4 CapEx < $42.7M^[FMP]. Target: Consolidation in the band between current $326^[FMP] and median $315^[FMP]. ### Scenario C · Miss **EPS < $2.00 or CapEx ≥ $42.7M** Threshold: EPS < $2.00^{[FMP est×0.97]}. Target: Current $326 below SMA200 $262^[FMP], if rejection continues, $222^[derived] support activates. ## Risk Notes ### Primary segment below threshold Q1: EPS $2.13 vs $1.68 beat^[FMP], stock -1.1% D+1^[FMP]. ### Backlog concentration No RPO/backlog concentration disclosed in Q1 earnings call. ### Insider trading Form 4 data is marked in the table — this page does not generate assumptions for this stock. | Executive | Action | Amount | Date | |---|---|---|---| **Net:** — (0 transactions · 0 sells · 0 buys) · Q1 FY26 ### CapEx shock Q1 CapEx $42.7M^{[FMP cashflow]}. Robert McMahon Q1 transcript: "Capital expenditures were $43 million, down from $71 million in the prior year as we continue to drive a focus on increased capital spending efficiency."^{[Robert McMahon transcript]}. Q1 op margin 21.0%^{[FMP op margin]} — this level in Q4 is sensitive to CapEx revision risk. ## Wall Street Consensus - **Median target:** $315 (-3.4% upside vs current $326) - **High / Low:** $340 / $295 - **Buy / Hold / Sell:** 12 / 3 / 0 - **Analyst count:** 6 (last quarter), 20 all-time ## Additional Transcript Insights ### 1. fy26_revenue_guidance_increase **Claim:** West is increasing its revenue and adjusted EPS guidance for full year 2026 due to strong first quarter performance and the expected ongoing momentum in its business. **Evidence (transcript):** "As announced in the press release today, due to our strong first quarter performance and the expected ongoing momentum in our business, we are increasing our revenue and adjusted EPS guidance for full year 2026." **Numbers:** 2026 ### 2. organic_revenue_growth_guidance **Claim:** West has increased its full year 2026 organic revenue growth expectation to 7% to 9%, up from its previous guide of 5% to 7%. **Evidence (transcript):** "We now anticipate full year organic revenue growth back to our long-term construct of 7% to 9%, up from our previous guide of 5% to 7%, and adjusted EPS increased to the range of $8.40 to $8.75." **Numbers:** 7%, 9%, 5%, 7%, $8.40, $8.75 ### 3. hvp_components_growth **Claim:** HVP components represents 48% of the company's total net sales and continues to be the key growth driver for West, growing 23% on an organic basis in the first quarter. **Evidence (transcript):** "Starting with HVP components in our proprietary Products segment, which represents 48% of our company's total net sales and continues to be the key growth driver for West. HVP components grew 23% on an organic basis in the first quarter." **Numbers:** 48%, 23% ### 4. glp-1_revenue_contribution **Claim:** HVP components GLP-1 revenues grew significantly and contributed 10% of total company sales consistent with the previous quarter. **Evidence (transcript):** "HVP components GLP-1 revenues grew significantly and contributed 10% of total company sales consistent with the previous quarter." **Numbers:** 10% ### 5. biologics_growth **Claim:** This business continues to be a strong growth driver for our HVP components business and delivered 26% organic growth. **Evidence (transcript):** "This business continues to be a strong growth driver for our HVP components business and delivered 26% organic growth." **Numbers:** 26% ### 6. annex_1_tailwind **Claim:** Annex 1 is anticipated to be a multiyear tailwind to our business with an expected revenue growth contribution of 200 basis points in 2026 from Annex 1 and HVP conversion. **Evidence (transcript):** "Annex 1 is anticipated to be a multiyear tailwind to our business with an expected revenue growth contribution of 200 basis points in 2026 from Annex 1 and HVP conversion." **Numbers:** 200, 2026 ### 7. capex_efficiency **Claim:** West continues to drive a focus on increased capital spending efficiency and remains on track with expectations of $250 million to $275 million for the year, even as it increases its revenue guidance. **Evidence (transcript):** "Capital expenditures were $43 million, down from $71 million in the prior year as we continue to drive a focus on increased capital spending efficiency. And we remain on track with our expectations of $250 million to $275 million for the year, even as we increase our revenue guidance, which I'll talk about shortly." **Numbers:** $43, $71, $250, $275 --- *Data source: FMP (live query, 2026-05-09), Q1 FY2026 earnings call transcript (Translated to EN with Gemini 2.0 Flash). Educational tool, not investment advice.*